Suchergebnisse - "Usmani, Saad Z"

PubPharm (28)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

3

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +19

4

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

enthalten in: Haematologica | 2022

von Usmani, S. | Nahi, H. | Legiec, W. | +25

5

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA

enthalten in: Leukemia | 2022

von Facon, T. | Cook, G. | Usmani, S. | +25

6

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

7

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

enthalten in: Blood | 2022

von San-Miguel, J. | Avet-Loiseau, H. | Paiva, B. | +24

CommentIn: Blood. 2022 Jan 27;139(4):469-471. - PMID 35084473

8

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study

enthalten in: The Lancet. Oncology | 2022

von Usmani, S. | Quach, H. | Mateos, M. | +15

CommentIn: Lancet Oncol. 2022 Mar;23(3):e97. - PMID 35240098

9

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Facon, T. | Kumar, S. | Plesner, T. | +26

10

Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma : results of the phase III study CANDOR by prior lines of therapy

enthalten in: British journal of haematology | 2021

von Quach, H. | Nooka, A. | Samoylova, O. | +12